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Abstract
Background: Magnesium and vitamin E are known to exert multiple beneficial effects, such as anti-glycemic
and anti-lipidemic properties. The aim of this study was to determine the effects of magnesium and vitamin
E co-supplementation on metabolic status of women with gestational diabetes (GDM).
Methods: This randomized, double-blinded, placebo-controlled trial was conducted among 60 subjects diagnosed
with GDM, aged 18–40 years. Subjects were randomly allocated into two groups to receive 250 mg/day magnesium
oxide plus 400 IU/day vitamin E supplements or placebo (n = 30 each group) for 6 weeks. Participants’ blood samples
were taken to determine their metabolic profiles.
Results: Subjects who received magnesium plus vitamin E supplements had significantly lower fasting plasma glucose
(β − 5.20 mg/dL; 95% CI, − 7.88, − 2.52; P = 0.002), serum insulin levels (β − 2.93 μIU/mL; 95% CI, − 5.68, − 0.18; P = 0.02)
and homeostasis model of assessment-insulin resistance (β − 0.78; 95% CI, − 1.42, − 0.14; P= 0.01), and higher quantitative
insulin sensitivity check index (β 0.01; 95% CI, 0.005, 0.02; P= 0.002) compared with placebo. In addition, magnesium plus
vitamin E supplementation resulted in a significant reduction in serum triglycerides (β − 50.31 mg/dL; 95% CI,
− 67.58, − 33.04; P < 0.001), VLDL- (β − 10.06 mg/dL; 95% CI, − 13.51, − 6.60; P < 0.001), total- (β − 26.10 mg/dL;
95% CI, − 41.88, − 10.33; P = 0.004), LDL- (β − 15.20 mg/dL; 95% CI, − 29.50, − 0.91; P = 0.03) and total-/HDL-cholesterol
ratio (β − 0.46; 95% CI, − 0.72, − 0.19; P < 0.001) compared with placebo. Magnesium and vitamin E co-supplementation
did not affect HDL-cholesterol levels.
Conclusions: Overall, magnesium and vitamin E co-supplementation for 6 weeks in women with GDM significantly
improved glycemic control and lipid profiles, except for HDL-cholesterol levels.
Clinical trial registration number: http://www.irct.ir: IRCT20170513033941N24.
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Background
Gestational diabetes mellitus (GDM) is defined as carbo-
hydrates intolerance which first recognized at second or
third trimester of pregnancy and has reported to in-
creasing worldwide [1]. It influences approximately 1 to
20% of all pregnancies worldwide as well as its preva-
lence among Iranian women is about 4 to 9% of all
pregnancies [2]. Both environmental risk factors and
genetic background contribute to the development of
GDM [3]. In addition to maternal and fetal complica-
tions, GDM is associated with the elevated potential for
metabolic disorder including type 2 diabetes mellitus
(T2DM) and cardiovascular disease (CVD) in future life of
both mother and offspring [4, 5]. In addition, insulin resist-
ance and dyslipidemia are the hallmarks of GDM [6, 7].
There is evidence demonstrating that magnesium is
required more during pregnancy [8]. In addition, hypo-
magnesemia might lead to impaired glucose tolerance
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[9]. Few studies have reported low circulating levels of
magnesium and vitamin E in women with GDM [10, 11].
Furthermore, several human studies have demonstrated
the beneficial effects of single magnesium [12] or vitamin E
supplementation on metabolic profiles. In a meta-analysis,
magnesium supplementation resulted in a significant re-
duction in insulin resistance, but did not affect fasting glu-
cose and insulin levels [13]. Earlier, we have shown that
magnesium supplementation for 6 weeks to women with
GDM led to a significant reduction in triglycerides and
VLDL-cholesterol levels, but did not affect other lipid pro-
files [14]. In addition, some studies have reported the bene-
ficial effects of vitamin E supplementation on glucose
metabolism and lipid profiles in patients with metabolic
syndrome [15, 16]. Recently, it has been suggested that
joint magnesium and vitamin E supplementation in dia-
betic rat was more beneficial to improve lipid profiles and
blood viscosity rather than magnesium alone [17]. In
another study, combined vitamin E and magnesium sup-
plementation could effectively improve triglycerides levels
of obese rats, better than vitamin E alone [18].
This evidence might suggest the importance of magne-
sium and vitamin E co-supplementation on metabolic
profiles in women with GDM. According to our best
knowledge, data on the effects of magnesium and vita-
min E co-supplementation on metabolic status of
patients with GDM are scarce. Therefore, the aim of this
study was to evaluate the effects of magnesium and
vitamin E co-supplementation on metabolic status of
patients with GDM.
Methods
Participants
This randomized, double-blinded, placebo controlled
clinical trial, registered in the Iranian website for regis-
tration of clinical trials (no: IRCT20170513033941N24),
was conducted among sixty women with GDM, aged
18–40 years and non-diabetic before pregnancy, diag-
nosed using American Diabetes Association guidelines
[19] from December 2017 through March 2018. The
study was approved by the ethics committee of Arak
University of Medical Sciences (AUMS) and written in-
formed consent was taken from all participants prior to
the commencement of the study. Exclusion criteria were;
taking magnesium and vitamin E supplements 3 months
before the intervention insulin therapy required during
the intervention, experiencing pre-eclampsia, eclampsia,
hypo and hyperthyroidism, and being smokers.
Study design
To decrease the effects of potential confounders, strati-
fied randomization was performed at the beginning of
the study for all participants according to age and BMI.
Then, participants in each block were randomly allocated
into two treatment groups to take either 250 mg/day
magnesium oxide (twenty-first Century, Arizona, USA)
and 400 IU/day vitamin E (Zahravi, Tabriz, Iran) or pla-
cebo (Barij Essence, Kashan, Iran) (n = 30 each group) for
6 weeks. Randomization assignment was conducted using
computer-generated random numbers. Randomization
and allocation concealment for both researchers and
participants were carried out by a trained staff at the
gynecology clinic. Compliance to the magnesium and
vitamin E intake was assessed through measuring serum
magnesium levels. The consumption of magnesium sup-
plements and placebos during the study was also checked
by asking subjects to return the medication containers
back and receiving brief daily cell phone reminders to take
the supplements. All patients were advised to maintain
their routine dietary habits without any changes in their
other lifestyle factors such as physical activity during the
study. All patients completed 3-day food records and
three physical activity records presented as metabolic
equivalents (METs) at weeks 0, 3, 6 of the treatment.
Assessment of anthropometric measures
Participants’ weight and height were measured using a
standard scale (Seca, Hamburg, Germany) in a fasting
status at baseline and after 6-weeks’ intervention. Body
mass index (BMI) was calculated as weight in kg divided
by height in meters squared.
Assessment of outcomes
In this study, glycemic control was considered as the pri-
mary outcome, and lipid profiles the secondary outcomes.
Biochemical assessment
10 ml fasting blood samples were collected from partici-
pants at weeks 0 and 6 of the intervention. Commercial
kits were used to measure serum magnesium, fasting
plasma glucose (FPG), serum triglycerides, total-, VLDL-,
LDL- and HDL-cholesterol concentrations (Pars Azmun,
Tehran, Iran). Serum magnesium levels were measured
by enzymatic method. The inter- and intra-assay coeffi-
cient variances (CVs) for magnesium, FPG, lipid profiles
measurements were less than 5%. Serum insulin values
were assessed using an ELISA kit (Monobind, California,
USA) with the intra- and inter-assay CVs of lower than
6%. The homeostatic model of assessment for insulin re-
sistance (HOMA-IR) and the quantitative insulin sensi-
tivity check index (QUICKI) were determined according
to suggested formulas [20]. HOMA-IR was calculated
according to the following formula: fasting insulin (μIU/
mL) x fasting glucose (mmol/L)/22.5 [20]. QUICKI was
calculated as QUICKI = 1/[log(I0) + log(G0)], where I0 is
the fasting insulin, and G0 is the fasting glucose [20].
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Sample size
Type one (α) and type two errors (β) were defined as
0.05, and 0.20, respectively to have the study power of
80%. Based on a previous published study [14], we used
1.05 as the mean difference of the HOMA-IR and 1.30
as SD. Calculating sample size, we required 25 patients
in each treatment group; allowing for 20% dropouts in
each group, the final sample size was considered to be
30 patients per treatment group.
Statistical analyses
Kolmogorov-Smirnov test was done to determine the
normality of data. To detect the differences in anthropo-
metric measures and dietary intakes between treatment
groups, we used independent-samples t-test. To deter-
mine the effects of magnesium and vitamin E
co-supplementation on parameters of glucose homeosta-
sis and lipid profiles, we used general linear model and
one-way repeated measures analysis of variance. In this
analysis, treatment variable (magnesium plus vitamin E
vs. placebo) was regarded as between-subject factor and
time-points (baseline and week 6 of intervention) as
within-subject factor. The effect sizes were presented as
the mean differences with 95% confidence intervals.
P-values < 0.05 were considered statistically significant.
All statistical analyses were done using the Statistical
Package for Social Science version 18 (SPSS Inc., Chicago,
Illinois, USA).
Results
During the enrollment phase of the study, 65 women
with GDM were invited to participate in the trial; how-
ever, 5 participants were excluded from the study, due to
not meeting the inclusion criteria. Finally, 60 partici-
pants [placebo (n = 30) and magnesium plus vitamin E
(n = 30)] completed the trial (Fig. 1).
Mean age, height, weight and BMI at baseline and
after the 6-week treatment were not statistically different
between the two groups (Table 1).
Using 3-day dietary records, obtained during the inter-
vention, there was no statistically significant difference
in terms of dietary macro- and micro-nutrient intakes
between magnesium plus vitamin E and placebo groups
(Data not shown).
Subjects who received magnesium plus vitamin E supple-
ments had significantly lower FPG (β − 5.20 mg/dL; 95%
CI, − 7.88, − 2.52; P = 0.002), serum insulin levels (β − 2.93
μIU/mL; 95% CI, − 5.68, − 0.18; P = 0.02) and HOMA-IR (β
− 0.78; 95% CI, − 1.42, − 0.14; P = 0.01), and higher QUICKI
(β 0.01; 95% CI, 0.005, 0.02; P = 0.002) compared with
placebo (Table 2). In addition, magnesium plus vitamin E
supplementation resulted in a significant reduction in
serum triglycerides (β − 50.31 mg/dL; 95% CI, − 67.58,
− 33.04; P < 0.001), VLDL- (β − 10.06 mg/dL; 95% CI,
− 13.51, − 6.60; P < 0.001), total- (β − 26.10 mg/dL;
95% CI, − 41.88, − 10.33; P = 0.004), LDL- (β − 15.20 mg/
dL; 95% CI, − 29.50, − 0.91; P = 0.03) and total-/HDL-cho-
lesterol ratio (β − 0.46; 95% CI, − 0.72, − 0.19; P < 0.001)
Fig. 1 Summary of patient flow diagram
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rather than placebo group. Magnesium and vitamin E
co-supplementation did not affect HDL-cholesterol levels.
Discussion
In the present study, we examined the effects of
co-supplementation of magnesium and vitamin E on
parameters of glucose homeostasis and lipid profiles in
women with GDM. We found that magnesium and vita-
min E co-supplementation to women with GDM for
6 weeks improved glycemic control and lipid concentra-
tions except for HDL-cholesterol values.
Gestational diabetes mellitus occurs because of altered
glucose metabolism and peripheral insulin resistance
[21]. Our study indicated that magnesium and vitamin E
co-administration to women with GDM lowered serum
FPG, insulin levels and HOMA-IR, and led to a
significant rise in QUICKI. Similar to our findings, a
meta-analysis conducted by Simental-Mendia et al. [13]
revealed that magnesium supplementation for at least
4 months improved FPG and HOMA-IR in both diabetic
and non-diabetic individuals. In addition, our previous
study indicated that a 6-week co-supplementation with
magnesium and other nutrients in patients with GDM
had beneficial effects on FPG, insulin levels, HOMA-IR
and QUICKI [22]. Moreover, Rafraf et al. [23] reported
that vitamin E supplementation to people with T2DM
for 8 weeks reduced serum FPG levels. However, some
researchers failed to find the beneficial effects of magne-
sium [24] or vitamin E supplementation on glycemic
control. For instance, in a meta-analysis conducted by
Xu et al. [25], vitamin E supplementation did not affect
parameters of insulin metabolism. In addition, a
Table 1 General characteristics of study participants
Placebo group (n = 30) Magnesium plus vitamin E group (n = 30) P1
Age (y) 31.5 ± 3.2 30.1 ± 5.9 0.25
Height (cm) 162.3 ± 4.5 162.5 ± 5.1 0.89
Weight at study baseline (kg) 73.7 ± 7.7 72.7 ± 12.6 0.74
Weight at end-of-trial (kg) 75.1 ± 7.7 74.1 ± 12.5 0.70
Weight change (kg) 1.4 ± 0.4 1.3 ± 0.5 0.33
BMI at study baseline (kg/m2) 28.0 ± 3.1 27.6 ± 4.7 0.68
BMI at end-of-trial (kg/m2) 28.5 ± 3.1 28.0 ± 4.7 0.64
BMI change (kg/m2) 0.5 ± 0.2 0.5 ± 0.2 0.29
Data are means± standard deviation
1 Obtained from independent sample t-test
Table 2 The effect of magnesium and vitamin E co-supplementation on metabolic status in women with gestational diabetes
Variables Placebo group (n = 30) Magnesium plus vitamin E group
(n = 30)
Difference in outcome measures between intervention
and placebo treatment groups1
Baseline Week 6 Baseline Week 6 β (95% CI) P2
Magnesium (mg/dL) 2.07 ± 0.15 2.02 ± 0.15 2.04 ± 0.22 2.18 ± 0.13 0.17 (0.11, 0.23) < 0.001
FPG (mg/dL) 91.9 ± 5.6 91.8 ± 6.4 90.3 ± 6.2 85.4 ± 5.9 −5.20 (−7.88, −2.52) 0.002
Insulin (μIU/mL) 13.4 ± 4.1 14.9 ± 8.9 13.2 ± 3.6 11.5 ± 3.7 −2.93 (−5.68, −0.18) 0.02
HOMA-IR 3.0 ± 0.9 3.3 ± 2.0 3.0 ± 0.8 2.4 ± 0.8 −0.78 (−1.42, − 0.14) 0.01
QUICKI 0.32 ± 0.01 0.32 ± 0.02 0.32 ± 0.01 0.33 ± 0.02 0.01 (0.005, 0.02) 0.002
Triglycerides (mg/dL) 208.9 ± 52.1 54.2 206.3 ± 63.5 169.1 ± 65.9 −50.31 (−67.58, −33.04) < 0.001
VLDL-cholesterol (mg/dL) 41.8 ± 10.4 44.5 ± 10.8 41.2 ± 12.7 33.8 ± 13.2 −10.06 (−13.51, −6.60) < 0.001
Total cholesterol (mg/dL) 229.5 ± 41.2 232.9 ± 42.4 223.3 ± 49.0 201.3 ± 46.7 −26.10 (−41.88, − 10.33) 0.004
LDL-cholesterol (mg/dL) 130.3 ± 36.4 131.6 ± 39.0 127.9 ± 41.7 113.4 ± 45.5 −15.20 (−29.50, −0.91) 0.03
HDL-cholesterol (mg/dL) 57.4 ± 13.2 56.8 ± 11.3 54.1 ± 9.6 54.0 ± 8.7 0.70 (−3.07, 2.09) 0.68
Total-/HDL-cholesterol ratio 4.1 ± 1.0 4.2 ± 1.0 4.2 ± 0.8 3.8 ± 0.8 −0.46 (−0.72, − 0.19) < 0.001
Data are mean ± SDs
1”Outcome measures” refers to the change in values of measures of interest between baseline and week 6. β [difference in the mean outcomes measures
between treatment groups (magnesium plus vitamin E group = 1 and placebo group = 0)]
2 P values represent the time × group interaction (computed by analysis of the repeated measures ANOVA)
FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol,
low density lipoprotein-cholesterol; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol
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3-month magnesium supplementation in hypomagnesic
pre-diabetic patients with chronic kidney disease did not
change FPG levels [26].
Maternal insulin resistance in GDM might increase pla-
cental size, though decrease placental efficiency, subse-
quently might affect fetal growth [27]. It also has been
demonstrated that well glycemic control may improve
pregnancy outcomes [28]. Magnesium is involved in glu-
cose metabolism through its effects on tyrosine kinase ac-
tivity of the insulin receptors [29]. It also regulates glucose
uptake via its influence on glucose transporte-4 activity
[29], and regulates oxidative pathway of glucose metabol-
ism through the activation of pyruvate dehydrogenas [30].
Furthermore, the beneficial effects of vitamin E intake on
insulin resistance may be explained through its effect on
suppressing oxidative stress and gene expression of per-
oxisome proliferator activated-receptor (PPAR) alpha [31].
Also, vitamin E can mediate glucose metabolism by stimu-
lating glutathione and magnesium levels [32].
Gestational diabetes mellitus is accompanied by lipid
profiles changes including an elevated triglyceride, total-
and LDL-cholesterol levels [33]. In the present study, we
observed that magnesium and vitamin E
co-supplementation to women with GDM reduced tri-
glycerides, VLDL-, total-, LDL- and total-/HDL-choles-
terol, but did not affect HDL-cholesterol levels. In
agreement with our findings, the results of another clin-
ical study indicated that magnesium supplementation for
4 months decreased triglycerides levels in pre-diabetic
patients with hypomagnesemia [34]. Consistent with our
results, Ekhlasi et al. [35] reported that synbiotic and
vitamin E co-supplementation reduced triglycerides,
total- and LDL-cholesterol levels, but did not affect
HDL-cholesterol concentrations. Moreover, a significant
reduction in total cholesterol levels was reported after
vitamin E supplementation to women with metabolic
syndrome [36]. In contrast, in a meta-analysis conducted
by Xu et al. [25] there was no significant effects of vita-
min E supplementation on lipid profiles. On the other
hand, magnesium supplementation could not improve
lipid levels in both diabetic and non-diabetic individuals
[37]. Hypertriglyceridemia during pregnancy worsen in-
sulin resistance [38] and seems to be an independent
predictor of fetal macrosomia [39]. Recent studies have
reported a positive association between maternal triglyc-
erides levels and the risk of large for gestational age neo-
nate, independent of glycemic controls [40]. Magnesium
acts as the cofactor of lipoprotein lipase which induces
chylomicrone clearance and delays postprandial increase
in triglycerides levels [41]. Vitamin E, beside its antioxi-
dant effects, modulates gene expression of PPAR gama,
which involves in lipid metabolism [42].
Our study had a few limitations. Due to lack of enough
funding, we could not evaluate the effects of magnesium
and vitamin E co-supplementation on gene expression of
insulin and lipid metabolism. We also did not measure
vitamin E levels. In addition, further studies are necessary
with single supplementation for each comparison with
co-supplementation to assess the beneficial effects of each
supplement on glycemic control and lipid profiles. Higher
confidence interval of dependent variables found in some
cases might make the findings difficult to be interpreted.
Higher confidence interval might be explained by the
small sample size in the included studies, which is another
limitation of our study and thus more trials with larger
sample size would be needed to confirm our findings.
Conclusions
Overall, magnesium and vitamin E co-supplementation
for 6 weeks in women with GDM significantly im-
proved glycemic control and lipid profiles except for
HDL-cholesterol levels.
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